Screener
BioCryst Pharmaceuticals BCRX Royalty financing obligations
Royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:RoyaltyFinancingLiabilitiesNoncurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 208,846 | 196,066 |
| Operating lease liabilities | 10,603 | 8,571 |
| Finance lease liabilities | 849 | 1,441 |
| Royalty financing obligations | 382,981 | 427,233 |
| Secured term loan | 395,400 | — |
| Deferred revenue | 13,461 | — |
| Total liabilities | 1,012,140 | 633,311 |
| Stockholders’ deficit: |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported royalty financing obligations of $382.98M in Q2 2026.
- How has BioCryst Pharmaceuticals's royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's royalty financing obligations decreased by 14.5% year-over-year, from $447.84M to $382.98M.
- What is the long-term trend for BioCryst Pharmaceuticals's royalty financing obligations?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's royalty financing obligations has grown at a -8.3% compound annual growth rate (CAGR), from $508.03M to $427.23M.
- What does royalty financing obligations mean?
- Royalty financing obligations as reported by BioCryst Pharmaceuticals Inc.
Ask your AI about BioCryst Pharmaceuticals's royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude